Intuitive Surgical, Inc. $ISRG Position Boosted by Braidwell LP

Braidwell LP raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,600 shares of the medical equipment provider’s stock after acquiring an additional 1,600 shares during the period. Intuitive Surgical makes up 1.7% of Braidwell LP’s holdings, making the stock its 22nd largest position. Braidwell LP’s holdings in Intuitive Surgical were worth $48,690,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in ISRG. Brighton Jones LLC raised its stake in shares of Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after purchasing an additional 731 shares in the last quarter. Sit Investment Associates Inc. increased its stake in Intuitive Surgical by 15.5% during the 1st quarter. Sit Investment Associates Inc. now owns 20,089 shares of the medical equipment provider’s stock valued at $9,949,000 after buying an additional 2,694 shares during the period. Vestmark Advisory Solutions Inc. raised its position in shares of Intuitive Surgical by 95.0% during the 1st quarter. Vestmark Advisory Solutions Inc. now owns 17,144 shares of the medical equipment provider’s stock worth $8,491,000 after buying an additional 8,350 shares in the last quarter. Kovitz Investment Group Partners LLC lifted its stake in shares of Intuitive Surgical by 0.9% in the 1st quarter. Kovitz Investment Group Partners LLC now owns 7,847 shares of the medical equipment provider’s stock worth $3,887,000 after acquiring an additional 72 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Intuitive Surgical by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 574,954 shares of the medical equipment provider’s stock valued at $284,746,000 after acquiring an additional 8,521 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on ISRG shares. Citigroup cut Intuitive Surgical from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $650.00 to $635.00 in a report on Thursday. Piper Sandler boosted their price objective on Intuitive Surgical from $595.00 to $610.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Zacks Research raised Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 24th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Intuitive Surgical in a research report on Friday, August 22nd. Finally, Truist Financial set a $620.00 price objective on shares of Intuitive Surgical and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $608.79.

Insiders Place Their Bets

In related news, EVP Henry L. Charlton sold 13,731 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total transaction of $7,963,980.00. Following the transaction, the executive vice president directly owned 3,056 shares of the company’s stock, valued at approximately $1,772,480. The trade was a 81.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gary S. Guthart sold 22,806 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $570.89, for a total value of $13,019,717.34. Following the sale, the insider owned 2,694 shares of the company’s stock, valued at $1,537,977.66. The trade was a 89.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 109,043 shares of company stock worth $60,816,225 in the last quarter. Corporate insiders own 0.70% of the company’s stock.

Intuitive Surgical Stock Down 0.9%

Shares of NASDAQ ISRG opened at $542.32 on Friday. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00. The company has a market cap of $194.41 billion, a price-to-earnings ratio of 71.74, a P/E/G ratio of 5.03 and a beta of 1.68. The business has a fifty day simple moving average of $529.62 and a 200-day simple moving average of $506.00.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The firm had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the previous year, the company earned $1.84 EPS. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.